November 27, 2007 - Medrad Inc. displayed at RSNA 2007 “CT Contrast Injection of the Future,” an exhibit about the leading role of contrast injection in CT imaging, as well as patient safety, patient-specific protocol optimization and workflow and data integration innovations that are in development by the company.
Medrad also highlighted advancements made to its Stellant CT Injection System, featuring the DualFlow simultaneous injection and scanner-injector interface technology, as well as two new additions: CardiacFlow powered by P3TTM and XDSTM Extravasation Detector.
CardiacFlow is the first application of Medrad’s P3T, Personalized Patient Protocol Technology, which uses patient-specific parameters to optimize injection timing and contrast volume, and is specifically designed for cardiac CT imaging procedures. It is U.S. FDA 510(k) pending and patent pending.
The Medrad XDS Extravasation Detector is a patented product designed to prevent moderate to severe contrast extravasations that may seriously injure patients. Because XDS technology directly senses fluid pooling under the skin to stop an injection during a CT procedure, it reportedly minimizes false positives to maintain efficient workflow. XDS is U.S. FDA 510(k) cleared as of March 2007.
For more information: www.medrad.com
April 22, 2024 
